{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-029654","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.716029+00:00","generated_at":"2026-05-24T02:46:42.517759+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Theriva Biologics: second IDMC review finds VCN-01 well tolerated in metastatic PDAC trial","bullets":["IDMC reviewed safety data from 101 patients across 14 sites in US and Spain.","VCN-01 AE profile consistent with prior trials; AEs transient and reversible, less frequent after second dose.","Patient enrollment completed Sep 2024; topline clinical outcomes data expected Q2 2025.","CEO says positive data, along with prior FDA/EMA feedback, could guide Phase 3 registrational trial design."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-029654","json":"https://secwatch.observer/filing/0001104659-25-029654.json","markdown":"https://secwatch.observer/filing/0001104659-25-029654.md","text":"https://secwatch.observer/filing/0001104659-25-029654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/0001104659-25-029654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925029654/tm2510883d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:46:42.517759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}